Unknown

Dataset Information

0

Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of A? Plaques in Alzheimer's Disease.

ABSTRACT: Currently, there is no gadolinium-based contrast agent available for conventional magnetic resonance imaging (MRI) detection of amyloidal beta (A?) plaques in Alzheimer's disease (AD). Its timely finding would be vital for patient survival and quality of life. Curcumin (CUR), a common Indian spice effectively binds to A? plaques which is a hallmark of AD. To address this binding, we have designed a novel nanoimaging agent (NIA) based on nature-derived poly(?-l-malic acid) (PMLA) containing covalently attached gadolinium-DOTA(Gd-DOTA) and nature-derived CUR. The all-in-one agent recognizes and selectively binds to A? plaques and is detected by MRI. It efficiently detected A? plaques in human and mouse samples by an ex vivo staining. The method can be useful in clinic for safe and noninvasive diagnosis of AD.

SUBMITTER: Patil R 

PROVIDER: S-EPMC4794283 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Curcumin Targeted, Polymalic Acid-Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease.

Patil Rameshwar R   Gangalum Pallavi R PR   Wagner Shawn S   Portilla-Arias Jose J   Ding Hui H   Rekechenetskiy Arthur A   Konda Bindu B   Inoue Satoshi S   Black Keith L KL   Ljubimova Julia Y JY   Holler Eggehard E  

Macromolecular bioscience 20150602 9

Currently, there is no gadolinium-based contrast agent available for conventional magnetic resonance imaging (MRI) detection of amyloidal beta (Aβ) plaques in Alzheimer's disease (AD). Its timely finding would be vital for patient survival and quality of life. Curcumin (CUR), a common Indian spice effectively binds to Aβ plaques which is a hallmark of AD. To address this binding, we have designed a novel nanoimaging agent (NIA) based on nature-derived poly(β-l-malic acid) (PMLA) containing coval  ...[more]

Similar Datasets

Unknown Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases.
| S-EPMC7007242 | biostudies-literature
Unknown Gadolinium-based MRI contrast agent for the detection of tyrosinase.
| S-EPMC7028485 | biostudies-literature
Unknown Design of a modular protein-based MRI contrast agent for targeted application.
| S-EPMC3675113 | biostudies-literature
Unknown Detection of Sulfatase Enzyme Activity with a CatalyCEST MRI Contrast Agent.
| S-EPMC4877021 | biostudies-literature
Unknown Detection of DT-diaphorase Enzyme with a ParaCEST MRI Contrast Agent.
| S-EPMC6010184 | biostudies-literature
Unknown Novel membrane-permeable contrast agent for brain tumor detection by MRI.
| S-EPMC3819103 | biostudies-literature
Unknown MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent.
| S-EPMC4557274 | biostudies-literature
Unknown Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease.
| S-EPMC7527957 | biostudies-literature
Unknown A biomarker-responsive T2ex MRI contrast agent.
| S-EPMC5071101 | biostudies-literature
Unknown Early detection and staging of chronic liver diseases with a protein MRI contrast agent.
| S-EPMC6820552 | biostudies-literature